Best Gas Utility Companies To Watch In Right Now

Point State Capital�� Zack Schreiber thinks U.S. crude oil prices are headed lower, but he would match his idea to short crude oil with two advantaged U.S. refiners.

Associated Press

He likes Valero Energy (VLO) and Marathon Petroleum (MPC); shares were up slightly in late afternoon trading. These refiners are returning cash in the form of dividends and stock buybacks. ��e think the upside is at least 60%,��said Schreiber.

The refiners��costs are based on the U.S. crude oil price, but their prices are set based on international benchmarks. The spread between WTI and Brent crude, the international benchmark, as reflected in current stock prices, is too narrow.

The reason to like Valero Energy and Marathon Petroleum: free cash flow yields are attractive and strong balance sheets. And, each has a master limited partnership that it can put more assets into, a valuable structure for tax-saving that results and higher valuations for those assets “dropped” into the MLP. But this is ��assively undervalued in the current stock prices,��he said.

Best Gas Utility Companies To Watch In Right Now: Avanir Pharmaceuticals Inc(AVNR)

Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The company primarily offers NUEDEXTA, a unique proprietary combination of dextromethorphan and low-dose quinidine for the treatment of pseudobulbar affect. Its product line also comprises AVP-923 in Phase II clinical trial for the treatment of central neuropathic pain in patients with multiple sclerosis; and in Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. In addition, the company provides Docosanol 10% cream, an over-the-counter product for cold sores treatment. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.

Advisors' Opinion:

• [By Rebecca McClay]

  Finally, Avanir Pharmaceuticals Inc. (Nasdaq: AVNR) is up about 7% today after it settled with Actavis South Atlantic and Actavis Inc. (NYSE: ACT) to resolve pending patent litigation regarding ACT's seeking approval to market generic versions of AVNR's NUEDEXTA capsules. ACT is up about 1%.

Best Gas Utility Companies To Watch In Right Now: Akorn Inc.(AKRX)

Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various specialty areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, and vaccines. The company?s Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others primarily for use in the office setting. This segment also offers therapeutic products, such as antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; and non-pharmaceutical products, which include various artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers. In addit ion, the Ophthalmic segment provides a line of over-the-counter dry eye and other eye health products principally under the TheraTears brand name through a chain drug stores and big box retailers, as well as directly to optometrists, ophthalmologists, and other eye care practitioners and clinics. The company?s Hospital Drugs and Injectables segment provides a line of niche hospital drug and injectable pharmaceutical products comprising antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other pharmaceutical products to hospitals through the wholesale distribution channel. Its Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. The company serves physicians, optometrists, hospitals, wholesalers, group purchasing organizations, pharmacy chains, and other pharmaceutical companies. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Advisors' Opinion:

• [By Ben Levisohn]

  Still, some stocks are bucking the trend. Goodyear Tire & Rubber (GT) has gained 1.4% to $18.90, the largest gainer in the S&P 500, after reaching a deal with a union. The real winners: Hi-Tech Pharmacal (HITK) has gained 22.3% to $43.05 after agreeing to be purchased by Akorn (AKRX), which has jumped 9.6% to $18.02.

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of Akorn (NASDAQ: AKRX) were down 9.41 percent to $23.39 after the company reported Q4 results and issued a weak FY14 guidance.

• [By Sean Williams]

  What: Shares of Akorn (NASDAQ: AKRX  ) �-- a hybrid generic and branded drug developer -- shed as much as 15% of their value after the company reported disappointing first-quarter results.

Best Defense Stocks For 2015: Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.

The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.

MM-398

MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.

The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.

MM-121

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.

MM-111

MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.

MM-302

MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.

MM-151

MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.

Advisors' Opinion:

• [By Eric Volkman]

  Merrimack Pharmaceuticals (NASDAQ: MACK  ) is gearing up for a double dose of fund-raising. The company announced that it will concurrently float both a common stock and a convertible notes issue in a public offering. In the former, Merrimack will offer $50 million worth of shares, while the latter will take the form of $75 million in senior notes maturing in 2020. Additionally, the company expects that it will grant its underwriters a 30-day purchase option for up to an additional $7.5 million worth of common shares and $11.25 million of the convertible notes.

• [By Roberto Pedone]

  One under-$10 biopharmaceuticals player that's just starting to trigger a breakout trade is Merrimack Pharmaceuticals (MACK), which focuses on discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. This stock has been hit hard by the bears so far in 2013, with shares off by 38%.

  If you take a look at the chart for Merrimack Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last two months, with shares plunging from its high of 7.09 to its recent low of $3.26 a share. During that move, shares of MACK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of MACK have just formed a double bottom chart pattern at $3.26 to $3.32 a share and it's now starting to break out above some near-term overhead resistance at $3.64 a share. This move could be signaling a trend change for MACK as the stock starts to move higher off oversold conditions.

  Traders should now look for long-biased trades in MACK if it manages to break out above some near-term overhead resistance at $3.64 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout triggers soon, then MACK will set up to re-test or possibly take out its next major overhead resistance level at its 50-day moving average of $4.75 a share. Any high-volume move above that level and above more resistance at $5.06 will then give MACK a chance to tag its 200-day moving average at $5.71 a share.

  Traders can look to buy MACK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.32 or at $3.26 a share. One can also buy MACK off strength once it clears $3.64 a share with volume and then simply use a stop tha

Best Gas Utility Companies To Watch In Right Now: LM Ericsson Telephone Company(ERIC)

LM Ericsson Telephone Company provides communications equipment, professional services, and multimedia solutions to mobile and fixed networks operators worldwide. The Networks segment delivers radio access solutions that interconnect with devices, such as mobile phones, notebooks, and PCs; fixed access solutions for fiber and copper; and IP core network solutions, including softswitches, IP infrastructure for edge- and core routing, IP multimedia subsystem, and media gateways. This segment also offers transmission/backhaul; and microwave and optical transmission solutions for mobile and fixed networks, as well as offers network management tools for configuration, performance monitoring, security management, inventory management, and software upgrades. The Global Services segment delivers managed services comprising network design and planning, network operations, field operations and site maintenance, and shared solutions, as well as consulting and systems integration, cus tomer support, and network rollout services. The Multimedia segment provides IPTV solutions, video compression, on-demand solutions, content management systems, advertising, and interactive TV applications for operators, service providers, advertisers, and content providers; and business support systems, including revenue management, customer care, provisioning, device management, and analytics. This segment also offers service delivery platforms, communication suite, messaging, social media portal, and location-based services for consumers; and business communication solutions, such as business communication suite and brokering solutions that facilitate payment and distribution of content. The Sony Ericsson segment offers mobile phones, accessories, content, and applications. The ST-Ericsson segment develops and sells semiconductors and wireless platforms to handset manufacturers, mobile operators, and device manufacturers. The company was founded in 1876 and is headquarter ed in Stockholm, Sweden.

Advisors' Opinion:

• [By Paul Ausick]

  A report today from Bloomberg News cites people familiar with the matter who say that NSN is considering a workforce reduction of 8,500, bringing its total employee count down from around 50,500 to 42,000. NSN already has�chopped 20,000 workers in the past two years as the company faces increased competition from Ericsson (NASDAQ: ERIC) and Chinese firms Huawei Technologies and ZTE.

Best Gas Utility Companies To Watch In Right Now: Shionogi & Co Ltd (SGIOF.PK)

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company. It is engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides vitamin preparations, analgesic antipyretics, eye care products, cold and sinus medicine, digestive medicine, dermatologic preparations, antiphlogistic analgetics, antihypercholesterolemic agents, test paper for glucose in urine and artificial teeth-related products. As of March 31, 2013, the Company had 32 consolidated subsidiaries and six associated companies. Advisors' Opinion:

• [By Jason Melehani]

  ViiV Healthcare, a collaborative HIV focused venture established by GlaxoSmithKline (GSK), Pfizer (PFE) and Shionogi & Co (SGIOF.PK), is seeking approval from the FDA and the European Union for dolutegravir, an integrase inhibitor used for the treatment of HIV. Integrase inhibitors act by preventing the reverse transcribed viral DNA from integrating into the human T cell DNA.

Best Gas Utility Companies To Watch In Right Now: PhilWeb Corp (WEB)

PhilWeb Corporation is a Philippines-based Internet gaming company. The Company focused its activities on building its Internet-based products and services. The Company is engaged in providing products and services within a particular economic environment. It operates in two geographical segments: domestic operations and foreign operations. Its subsidiaries include BigGame, Inc., operates Internet casino station operations; Premayo sa Resibo, Inc., develops and markets computer systems, applications, programs and operates gaming platforms; PhilWeb Casino Corporation, develops, engages and maintains gaming systems and applications for all types of casino operations; e-Magine Gaming Corporation, develops technology, and PhilWeb Leisure & Tourism Corporation, establishes, operates and maintains leisure and tourism-oriented activities. Effective December 13, 2013, ePLDT Inc, a wholly owned unit of Philippine Long Distance Telephone Co acquired a 27.283% interest in Philweb Corp. Advisors' Opinion:

• [By Geoff Gannon]

  Always touchable money is cash. For individuals, there's little reason for it not to be a simple bank account, money market fund, etc. For most investors, you can just let this stock sit in your brokerage account. Many brokers will sweep unused cash into a money market account ��or other form of savings ��where it can earn a tiny amount of interest for you while staying totally liquid. One advantage of keeping cash in this form is that you can look at your cash and stock positions on the same (web)page any time you want. So, for example, if you know you want to keep 10% of your portfolio in cash ��you can see that you have $12,000 in cash as part of your $120,000 brokerage account and that means you are right on target with your liquidity goal.

Best Gas Utility Companies To Watch In Right Now: Western Asset Global Partners Income Fund Inc. (GDF)

Western Asset Global Partners Income Fund Inc. operates as a close-ended fixed income mutual fund launched and advised by Legg Mason Partners Fund Advisor, LLC. The fund is sub-advised by Western Asset Management Company. It primarily invests in the fixed income markets across the globe. The fund invests in high-yield U.S. and non-U.S. corporate debt securities and high-yield foreign sovereign debt securities. It benchmarks the performance of its portfolio against the Lehman Brothers U.S. Corporate High Yield 2% Issuer Cap Index and the JPMorgan Emerging Markets Bond Index Global Index. The fund was formerly known as Salomon Brothers Global Partners Income Fund Inc. Western Asset Global Partners Income Fund was founded in 1993 and is based in the United States.

Advisors' Opinion:

• [By Chuck Carnevale]

  Our first example looks at Vectren Corp.�� historical earnings, a utility with a 15-year historical earnings growth rate that is below our 3% threshold established in Part 1. Note that fair valuation is calculated using Graham Dodd�� Formula (GDF) deriving a fair value PE of 13.8 (slightly below, but close to our PE 15 standard). However, a normal PE of 16 has been historically applied by Mr. Market. Therefore, valuation falls between a PE of 13.8 to 16, or well within a range of normalcy.

Best Gas Utility Companies To Watch In Right Now: OM Group Inc.(OMG)

OM Group, Inc. develops, produces, and markets specialty chemicals, advanced materials, and electrochemical energy storage products worldwide. The company operates in three segments: Advanced Materials, Specialty Chemicals, and Battery Technologies. The Advanced Materials segment manufactures inorganic products using unrefined cobalt and other metals and serves the battery materials, powder metallurgy, ceramics, and chemical end markets. It offers cobalt powders, precursors, chemicals, pigments and ceramics, and various raw materials. These products enhance the electrical conduction of rechargeable batteries, as well as strengthen and add durability to diamond and machine cutting tools and drilling equipment. The Specialty Chemicals segment offers electronic chemicals for the printed circuit board, memory disk, general metal finishing, electronic packaging and finishing, and photovoltaic markets. This segment also provides advanced organics comprising additives and driers for paints, and printing inks; rubber adhesion promoters for tires; composite and other catalysts for chemicals; and fuel oil additives, lubricants, and grease additives. In addition, it offers ultra pure chemicals used in the manufacture of electronic and computer components, such as semiconductors, wafers, and liquid crystal displays; and photo-imaging masks, including high-purity quartz or glass plates containing precision, microscopic images of integrated circuits; and reticles for the semiconductor, optoelectronics, and microelectronics industries under the Compugraphics brand name. The Battery Technologies segment provides battery products, primary and secondary batteries, battery management systems, battery chargers, and energetic devices for defense applications; primary and secondary batteries for satellites, aircraft, and the packaging of cells; and miniature batteries to power implantable medical devices. The company was founded in 1991 and is headquartered in Cle veland, Ohio.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of specialty chemical company OM Group (NYSE: OMG  ) climbed 14% today after its quarterly results easily topped Wall Street expectations.

• [By Canadian Value]

  Position % of Fund Assets 1) First American Financial Corp. (FAF) 7.0% 2) Apple, Inc. (AAPL) 6.5% 3) Coinstar, Inc. (CSTR) 4.8% 4) EMC Corp. (EMC) 4.4% 5) Coach, Inc. (COH) 4.4% 6) Kohl's Corp. (KSS) 4.1% 7) Blucora, Inc. (BCOR) 4.0% 8) Tetra Tech, Inc. (TTEK) 3.1% 9) OM Group, Inc. (OMG) 3.0% 10) American International Group, Inc. (AIG) 2.8% TOTAL 44.1% One area that we believe still offers some value in the market is in high quality, large��ap technology stocks that may be momentarily out��f��avor as they transition from rapid growth to slower growth. In particular, we become interested when that transition is also accompanied by a change in capital allocation policies designed to return more cash to shareholders in the form of dividends and share repurchases. We believe that Apple and EMC are two of the absolute highest quality technology businesses in the world and both have recently announced very material, shareholder��friendly changes to how they will allocate capital.

• [By Rich Smith]

  KMG Chemicals (NYSE: KMG  ) is buying OM Group's (NYSE: OMG  ) Ultra Pure Chemicals subsidiaries in the U.S., U.K., Singapore, and perhaps in France as well.

• [By Seth Jayson]

  There's no foolproof way to know the future for OM Group (NYSE: OMG  ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.